These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37202479)

  • 1. Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic pain.
    Campbell CM; Mun CJ; Hamilton KR; Bergeria CL; Huhn AS; Speed TJ; Vandrey R; Dunn KE
    Neuropsychopharmacology; 2023 Oct; 48(11):1630-1638. PubMed ID: 37202479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model.
    Dunn KE; Bergeria CL; Huhn AS; Speed TJ; Mun CJ; Vandrey R; Campbell CM
    Neuropsychopharmacology; 2021 Jul; 46(8):1451-1459. PubMed ID: 33879842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans.
    Babalonis S; Lofwall MR; Sloan PA; Nuzzo PA; Fanucchi LC; Walsh SL
    Psychopharmacology (Berl); 2019 Nov; 236(11):3341-3352. PubMed ID: 31201479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydromorphone for neuropathic pain in adults.
    Stannard C; Gaskell H; Derry S; Aldington D; Cole P; Cooper TE; Knaggs R; Wiffen PJ; Moore RA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD011604. PubMed ID: 27216018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.
    Huhn AS; Strain EC; Bigelow GE; Smith MT; Edwards RR; Tompkins DA
    Anesthesiology; 2019 Jan; 130(1):131-141. PubMed ID: 30418214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
    Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K
    Cochrane Database Syst Rev; 2022 May; 5(5):CD013444. PubMed ID: 35510826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers.
    Cooper ZD; Comer SD; Haney M
    Neuropsychopharmacology; 2013 Sep; 38(10):1984-92. PubMed ID: 23609132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.
    Cooper ZD; Bedi G; Ramesh D; Balter R; Comer SD; Haney M
    Neuropsychopharmacology; 2018 Sep; 43(10):2046-2055. PubMed ID: 29463913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.
    Lile JA; Kelly TH; Pinsky DJ; Hays LR
    Psychopharmacology (Berl); 2009 Apr; 203(2):241-50. PubMed ID: 19018520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabis-based medicines for chronic neuropathic pain in adults.
    Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
    Rauck R; Rapoport R; Thipphawong J
    Pain Pract; 2013 Jan; 13(1):18-29. PubMed ID: 22537100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Tolerability of Once-Daily OROS(®) hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: pooled analysis of 11 clinical studies.
    Nalamachu SR; Kutch M; Hale ME
    J Pain Symptom Manage; 2012 Dec; 44(6):852-65. PubMed ID: 22795050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.
    Lichtman AH; Lux EA; McQuade R; Rossetti S; Sanchez R; Sun W; Wright S; Kornyeyeva E; Fallon MT
    J Pain Symptom Manage; 2018 Feb; 55(2):179-188.e1. PubMed ID: 28923526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.
    Issa MA; Narang S; Jamison RN; Michna E; Edwards RR; Penetar DM; Wasan AD
    Clin J Pain; 2014 Jun; 30(6):472-8. PubMed ID: 24281276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Managing" the Placebo Effect: The Single-Blind Placebo Lead-in Response in Two Pain Models.
    Harden RN; Saracoglu M; Connolly S; Kirsling A; Comstock K; Khazey K; Gerson T; Burns J
    Pain Med; 2016 Dec; 17(12):2305-2310. PubMed ID: 28025364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydromorphone for cancer pain.
    Bao YJ; Hou W; Kong XY; Yang L; Xia J; Hua BJ; Knaggs R
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD011108. PubMed ID: 27727452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy.
    Narang S; Gibson D; Wasan AD; Ross EL; Michna E; Nedeljkovic SS; Jamison RN
    J Pain; 2008 Mar; 9(3):254-64. PubMed ID: 18088560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers.
    Schindler EAD; Schnakenberg Martin AM; Sewell RA; Ranganathan M; DeForest A; Pittman BP; Perrino A; D'Souza DC
    Psychopharmacology (Berl); 2020 Oct; 237(10):3097-3107. PubMed ID: 32632491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.